Buscar
Pharvaris NV
PHVSAñadir a la lista de seguimiento
33.070USD
-2.130-6.05%
Cierre 09-23 16:00（ET）
2.30BCap. mercado
PérdidaP/E TTM
Acerca de Pharvaris NV Compañía
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Perfil de Pharvaris NV
Símbolo de cotizaciónPHVS
Nombre de la empresaPharvaris NV
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoModig (Berndt B.A.E)
Número de empleados- -
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 05
DirecciónEmmy Noetherweg 2
CiudadLEIDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal2333 BK
Teléfono31712036410
Sitio Webhttps://pharvaris.com/
Símbolo de cotizaciónPHVS
Fecha de salida a bolsaFeb 05, 2021
Director ejecutivoModig (Berndt B.A.E)
Ejecutivos de Pharvaris NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Mr. David W. Nassif, J.D.
Mr. David W. Nassif, J.D.
Chief Financial Officer
Chief Financial Officer
191.62K
-5.22%
Dr. David P. Meeker ,M.D.
Dr. David P. Meeker ,M.D.
Non-Executive Director
Non-Executive Director
152.35K
+32.51%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Peng Lu, M.D., Ph.D.
Dr. Peng Lu, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
504.71K
-0.04%
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Dr. Anne Lesage, Ph.D.
Dr. Anne Lesage, Ph.D.
Co-Founder, Chief Early Development Officer
Co-Founder, Chief Early Development Officer
488.84K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Pharvaris NV?
Los cinco principales accionistas de Pharvaris NV son: Dr. Peng Lu, M.D., Ph.D.
¿Cuántas instituciones poseen acciones de Pharvaris NV (PHVS)?
A fecha de 2026Q1, 165 instituciones poseen acciones de Pharvaris NV, con un valor de mercado combinado de aproximadamente 59.26M, lo que representa el 90.60% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -451327.00.